Pfizer: Pulmonary Arterial Hypertension trials
The registry lists 11 Pulmonary Arterial Hypertension studies with Pfizer as lead sponsor. 0 are open to participants now and 7 have results posted.
Phase 1 4Phase 2 1Phase 3 4No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)CompletedNCT01445873Results posted
- A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple DosesTerminatedNCT01244620Phase 1Results posted
- A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed ThelinTerminatedNCT00995566Results posted
- A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial HypertensionTerminatedNCT00811018Phase 3Results posted
- Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding SildenafilTerminatedNCT00796666Phase 3Results posted
- Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term SafetyTerminatedNCT00796510Phase 3Results posted
- Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)TerminatedNCT00795639Phase 3Results posted
- A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial HypertensionCompletedNCT06137742Phase 1/2
- a Non-interventional Study of Sildenafil in the Treatment of Pulmonary Arterial Hypertension (PAH) in Adults From ChinaCompletedNCT05546125
- Drug Interaction Between Ritonavir And SitaxsentanWithdrawnNCT01251848Phase 1
- Effect Of Rifampin On Pharmacokinetics Of SitaxsentanWithdrawnNCT01251835Phase 1